Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Fluorodeoxyglucose (FluGlucoScan) in Patients With Breast Cancer: Correlation With Histologic Findings of Sentinel Node Biopsies and Axillary Dissection

NCT00123799 is registered in ClinicalTrials.gov with AHS Cancer Control Alberta as lead sponsor.

NCT NCT00123799
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00123799 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Fluorodeoxyglucose (FluGlucoScan) in Patients With Breast Cancer: Correlation With Histologic Findings of Sentinel Node Biopsies and Axillary Dissection
Lead sponsor
AHS Cancer Control Alberta
Phase
Phase 2
Overall status
Terminated
Start date
June 30, 2004
Completion date
April 30, 2007
Enrollment
199 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast neoplasms